Literature DB >> 23374735

Epidemiology of primary hyperparathyroidism.

Bart L Clarke1.   

Abstract

Primary hyperparathyroidism is the third most common endocrine disorder. The epidemiology of this disorder is increasingly well understood, but significant limitations still exist in our understanding of the mortality, hospitalizations, incidence, prevalence, and costs associated with this condition. These limitations are due to the small number of population-based epidemiologic studies that have evaluated this condition. Further studies will be required to fully characterize the epidemiology of primary hyperparathyroidism.
Copyright © 2013 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23374735     DOI: 10.1016/j.jocd.2012.11.009

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  12 in total

1.  Successful minimally invasive surgery for primary hyperparathyroidism: influence of preoperative imaging and intraoperative parathyroid hormone levels.

Authors:  Gaëtan-Romain Joliat; Nicolas Demartines; Luc Portmann; Ariane Boubaker; Maurice Matter
Journal:  Langenbecks Arch Surg       Date:  2015-11-21       Impact factor: 3.445

2.  Hospital care for primary hyperparathyroidism in Italy: a 6-year register-based study.

Authors:  Cristiana Cipriani; Vincenzo Carnevale; Federica Biamonte; Sara Piemonte; Jessica Pepe; Luciano Nieddu; John P Bilezikian; Salvatore Minisola
Journal:  Eur J Endocrinol       Date:  2014-07-11       Impact factor: 6.664

3.  The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis.

Authors:  Maryam Yavari; Awat Feizi; Fahimeh Haghighatdoost; Azin Ghaffari; Hassan Rezvanian
Journal:  Endocrine       Date:  2020-10-15       Impact factor: 3.633

4.  Justified follow-up: a final intraoperative parathyroid hormone (ioPTH) Over 40 pg/mL is associated with an increased risk of persistence and recurrence in primary hyperparathyroidism.

Authors:  Mohammad H Rajaei; Alex M Bentz; David F Schneider; Rebecca S Sippel; Herbert Chen; Sarah C Oltmann
Journal:  Ann Surg Oncol       Date:  2014-09-06       Impact factor: 5.344

Review 5.  Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.

Authors:  Benjamin Chevalier; Hippolyte Dupuis; Arnaud Jannin; Madleen Lemaitre; Christine Do Cao; Catherine Cardot-Bauters; Stéphanie Espiard; Marie Christine Vantyghem
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-06       Impact factor: 5.555

Review 6.  Role of Venous Sampling in the Diagnosis of Endocrine Disorders.

Authors:  Ryan W England; Eliza B Geer; Amy R Deipolyi
Journal:  J Clin Med       Date:  2018-05-14       Impact factor: 4.241

7.  18F-Fluorocholine PET and Multiphase CT Integrated in Dual Modality PET/4D-CT for Preoperative Evaluation of Primary Hyperparathyroidism.

Authors:  Valentin Pretet; Marianela Rotania; Mehdi Helali; Mihaela Ignat; Michel Vix; Alessio Imperiale
Journal:  J Clin Med       Date:  2020-06-26       Impact factor: 4.241

8.  Do Symptoms and Serum Calcium Levels Affect the Results of Surgical Treatment of Primary Hyperparathyroidism?

Authors:  QingAn Yu; KunPeng Liu; DaKun Ma; ChangMing Xie; YaoHua Wu; WenJie Dai; HongChi Jiang
Journal:  Biomed Res Int       Date:  2019-07-01       Impact factor: 3.411

9.  Is routine 24-hour urine calcium measurement useful during the evaluation of primary hyperparathyroidism?

Authors:  Shimena R Li; Kelly L McCoy; Helena E Levitt; Meghan L Kelley; Sally E Carty; Linwah Yip
Journal:  Surgery       Date:  2021-07-27       Impact factor: 3.982

Review 10.  Surgical options in treating patients with primary hyperparathyroidism.

Authors:  Masa Majcen; Marko Hocevar
Journal:  Radiol Oncol       Date:  2020-02-29       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.